The American Society for Law, Medicine & Ethics (ASLME) is pleased to announce the 4th annual bioIP Faculty Workshop on Friday April 26, 2019, at Boston University. The Workshop offers a unique opportunity for three scholars in their first decade of teaching to present their work in progress for in-depth critique and commentary by respected…
Join us in wonderful Copenhagen at our CeBIL Kick-Off Conference: ”Innovation Gaps on Life Science Frontiers? From Antimicrobial Resistance & the Bad Bugs to New Uses, AI & the Black Box”. The Conference marks the start of the Novo Nordisk Foundation’s Collaborative Research Programme in Biomedical Innovation Law which is carried out within a unique…
By Kevin Outterson Ironic that the leading argument against the President’s Executive Order 13768 on Sanctuary Cities is none other than the states’ rights / coercion arguments that convinced seven Justices to make the Medicaid expansion voluntary. Backstory on this element of National Federation of Independent Business (NFIB) v. Sebelius from 2012 here, with the abstract below:…
CALL FOR PARTICIPATION – ‘Research for Impact’ & the G20: How can global health innovation drive sustainable development? Date: April 28th 2017 Location: Central Berlin Time: 10:00-17:00 The G20 has underlined its commitment to contribute to the implementation of the 2030 Agenda, adopted by the United Nations in September 2015, as leaders look to cohere…
By Kevin Outterson Nick Bagley and I have an op-ed in today’s New York Times calling for serious economic incentives for antibiotics, delinking revenues from sales volumes with a $4 billion prize system. From the piece: On Friday, the Centers for Disease Control and Prevention released a disturbing report about the death of an elderly…
By Kevin Outterson Yesterday US HHS announced a new global partnership to fund pre-clinical antibiotic R&D, coordinated by the Boston University School of Law. The partnership is known as CARB-X, which is the abbreviation for the Combating Antibiotic-Resistant Bacteria (CARB) Biopharmaceutical Accelerator. CARB-X is the culmination of one key part of the US National Action Plan…
If you will be in DC on Thursday, we have a great meeting about economic incentives for antibiotic innovation. Location is Capitol Hill. Register here. Panelists include Rep. Peter Roskam (House Ways & Means), Sir Jim O’Neill, head of the UK AMR Review, Dr. Susan Coller Monarez, National Security Council and Christine Ardal, coordinator of WP2 (economic…
By Kevin Outterson Or so we claim in this month’s WHO Bulletin. Resistance is a global common pool problem requiring simultaneous action on three fronts: access to effective antibiotics (many more deaths from susceptible bacterial infections currently); conservation (protect and extend the most effective drug class in history through rational use and infection prevention); and innovation (new…
This new post by Kevin Outterson appears on the Health Affairs Blog, as part of part of a series stemming from the Third Annual Health Law Year in P/Review event held at Harvard Law School on Friday, January 30, 2015. Dame Sally Davies, the Chief Medical Officer of England, warns that we are approaching an antibiotic apocalypse. A…
By Abby Moncrieff We’ve heard a lot about “death spirals” and how they could stand in the way of the Affordable Care Act’s goal of a functioning individual health insurance marketplace. Seth Chandler has an interesting blog devoted to the subject, “ACA Death Spiral.” And those who have been following King v. Burwell, the Supreme…
